Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.

Introduction And Aim: A trivalent live attenuated influenza vaccine (Nasovac-S) was developed and licensed in India. A phase 4 study was conducted to assess safety.

Methodology: This non-randomized, open-label, single-arm study among individuals ≥ 2 years of age involved administration of 0.